Gilead Sciences, Inc. (GILD)

US — Healthcare Sector
Peers: AMGN  MRK  ABBV  JNJ  BMY  PFE  LLY  AZN 

Automate Your Wheel Strategy on GILD

With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GILD
  • Rev/Share 23.061
  • Book/Share 15.3114
  • PB 7.3634
  • Debt/Equity 1.3022
  • CurrentRatio 1.3693
  • ROIC 0.1532

 

  • MktCap 140862633200.0
  • FreeCF/Share 7.9005
  • PFCF 14.3095
  • PE 23.6542
  • Debt/Assets 0.4421
  • DivYield 0.0344
  • ROE 0.3171

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed GILD Cantor Fitzgerald -- Overweight -- $125 April 22, 2025
Reiterated GILD Oppenheimer -- Outperform $115 $132 March 4, 2025
Upgrade GILD Deutsche Bank Hold Buy -- $120 Feb. 18, 2025
Upgrade GILD DZ Bank Hold Buy -- $108 Feb. 13, 2025
Upgrade GILD Morgan Stanley Equal Weight Overweight $87 $113 Jan. 10, 2025
Resumed GILD BofA Securities -- Buy -- $109 Dec. 10, 2024
Upgrade GILD Leerink Partners Market Perform Outperform $74 $96 Oct. 21, 2024
Initiation GILD Bernstein -- Outperform -- $105 Oct. 17, 2024
Upgrade GILD Wells Fargo Equal Weight Overweight $78 $100 Oct. 7, 2024

News

Pharmaceutical Stocks Hit New Highs Amid Market Volatility
GILD
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative

During this time of heightened market volatility, it pays to be invested in the right places.

Read More
image for news Pharmaceutical Stocks Hit New Highs Amid Market Volatility
Gilead Sciences sets aside $200 million to resolve HIV drug probe
GILD
Published: March 03, 2025 by: Reuters
Sentiment: Negative

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.

Read More
image for news Gilead Sciences sets aside $200 million to resolve HIV drug probe
Why Gilead Sciences Remains A Buy After A 40% Rally
GILD
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive

Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year.

Read More
image for news Why Gilead Sciences Remains A Buy After A 40% Rally
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
GILD
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment o.

Read More
image for news Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
GILD or VRTX: Which Is the Better Value Stock Right Now?
GILD, VRTX
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?

Read More
image for news GILD or VRTX: Which Is the Better Value Stock Right Now?
Calls of the Day: Gilead Sciences and Merck
GILD, MRK
Published: February 18, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee debate the Calls of the Day in two biotech names.

Read More
image for news Calls of the Day: Gilead Sciences and Merck
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
GILD
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.

Read More
image for news Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
GILD
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
GILD
Published: February 12, 2025 by: Benzinga
Sentiment: Positive

Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.

Read More
image for news Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?
GILD
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
GILD
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral

Gilead Sciences, Inc. (NASDAQ:GILD ) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - CFO Cindy Perettie - EVP, Kite Conference Call Participants Geoff Meacham - Citigroup Terrence Flynn - Morgan Stanley Tim Anderson - Bank of America Umer Raffat - Evercore ISI Michael Yee - Jefferies Daina Graybosch - Leerink Partners Mohit Bansal - Wells Fargo Brian Abrahams - RBC Capital Markets Tyler Van Buren - TD Cowen …

Read More
image for news Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
GILD
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More
image for news Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Markets Mixed on Powell Testimony, Q4 Earnings
DASH, GILD, LYFT
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative

Tuesday, February 11, 2025 Market indexes were mixed today, after seeing all the majors in the red before the opening bell. The Dow closed up +123 points, +0.28%, while the S&P 500 squeaked by +2 points.

Read More
image for news Markets Mixed on Powell Testimony, Q4 Earnings
Gilead Sciences Beats Q4 EPS Forecast
GILD
Published: February 11, 2025 by: The Motley Fool
Sentiment: Positive

Gilead Sciences (GILD 0.69%), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated $1.74.

Read More
image for news Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
GILD
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Read More
image for news Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
ALNY, BIIB, GILD, MRNA, VRTX
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

Read More
image for news Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings
CMCSA, GILD, UBER
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral

Uber, Comcast, Gilead Sciences and Onfolio Holdings are included in this Analyst Blog.

Read More
image for news The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings
3 Fabulous Dividend Stocks to Buy in February
ABBV, AMGN, GILD
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.

Read More
image for news 3 Fabulous Dividend Stocks to Buy in February

About Gilead Sciences, Inc. (GILD)

  • IPO Date 1992-01-22
  • Website https://www.gilead.com
  • Industry Drug Manufacturers - General
  • CEO Daniel P. O'Day
  • Employees 17600

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.